期刊文献+

ARMS法在肺腺癌EGFR基因突变检测中的应用及意义 被引量:3

Application and significance of ARMS method in the detection of EGFR gene mutation in lung adenocarcinoma
下载PDF
导出
摘要 目的应用扩增阻滞突变系统(amplification refractory mutation system,ARMS)法检测肺腺癌不同标本类型表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变及其临床意义。方法收集厦门大学附属东南医院2019年1-12月肺腺癌标本232例,包括手术切除标本16例,肺活检标本126例,恶性胸腔积液细胞块标本35例,转移病灶标本55例,采用ARMS法检测EGFR基因突变,并分析EGFR基因突变在肺腺癌的临床意义。结果肺腺癌标本EGFR基因突变率44.83%(104/232)。年龄≥60岁者突变率为44.06%(63/143),年龄<60岁者突变率为46.07%(41/89),差异无统计学意义(P>0.05)。手术切除标本突变率为43.75%(7/16),肺活检标本突变率为38.89%(49/126),转移病灶标本突变率为47.27%(26/55),恶性胸腔积液细胞块标本突变率为62.86%(22/35),不同标本类型间突变率差异无统计学意义(P>0.05)。女性患者突变率(58.24%,53/91)高于男性(36.17%,51/141),差异有统计学意义(P<0.05)。结论ARMS法可用于肺腺癌不同标本类型EGFR基因突变检测;EGFR基因突变可能与患者性别有差异,与年龄及标本类型无差异。 Objective To investigate the gene mutation and clinical significance of epidermal growth factor receptor(EGFR)in different specimen types of lung adenocarcinoma patients using amplification refractory mutation system(ARMS).Methods A total of 232 lung adenocarcinoma specimens from the Affiliated Southeast Hospital of Xiamen University from January 2019 to December 2019 were collected for EGFR gene testing,including 16 cases of resected specimens,126 cases of lung biopsy specimens,35 cases of malignant pleural effusion cell block specimens,and 55 cases of metastatic lesions.The above specimens were tested for EGFR gene mutations using ARMS method,and the clinical significance of EGFR gene mutations in patients with lung adenocarcinoma was analyzed.Results The rate of EGFR gene mutation in lung adenocarcinoma specimens was 44.83%(104/232).The mutation rate was 44.06%(63/143)for those older than or equal to 60 years,and 46.07%(41/89)for those younger than 60 years,and there was no statistical difference(P>0.05).The rate of EGFR gene mutation was 43.75%(7/16)for resected specimen,38.89%(49/126)for lung biopsy specimen,47.27%(26/55)for metastatic lesion specimen,and 62.86%(22/35)for cell block specimen of malignant pleural effusion,and there was no statistical significance between different specimen types(P>0.05).The EGFR gene mutation rate was 36.17%(51/141)in male patients and 58.24%(53/91)in female patients(P<0.05).Conclusion ARMS method can be used to detect EGFR gene mutation in different specimen types of lung adenocarcinoma.EGFR gene mutations are related to gender,but not to age and specimen type.
作者 朱启淦 陈丽丹 禹乐 刘金发 任红岳 耿月华 魁国菊 孟加榕 ZHU Qigan;CHEN Lidan;YU Le;LIU Jinfa;REN Hongyue;GENG Yuehua;KUI Guoju;MENG Jiarong(Deparment of Pathology,909th Hospital of PLA,Dongnan Affiliated Hospital of Xiamen University,Zhangzhou 363000,China;Elderly Ward,909th Hospital of PLA,Dongnan Affiliated Hospital of Xiamen University)
出处 《山西医科大学学报》 CAS 2020年第8期744-748,共5页 Journal of Shanxi Medical University
基金 中国人民解放军联勤保障部队第九○九医院青年苗圃基金资助项目(17Y015,18Y017)。
关键词 扩增阻滞突变系统 表皮生长因子受体 肺腺癌 基因突变 amplification refractory mutation system EGFR lung adenocarcinoma gene mutation
  • 相关文献

参考文献11

二级参考文献79

  • 1BaoMingQIN,XiaoCHEN,JingDeZHU,DuanQingPEI.Identification of EGFR kinase domain mutations among lung cancer patients in China:implication for targeted cancer therapy[J].Cell Research,2005,15(3):212-217. 被引量:66
  • 2王超,周小鸽,余小蒙.细胞块免疫细胞化学和原位杂交在针吸细胞学中应用[J].临床与实验病理学杂志,2006,22(1):96-97. 被引量:26
  • 3Scagliotti GV,Selvaggi G,Novello S,et al. The biology of epidermal growth factor receptor in lung cancer.Clin Cancer Res,2004,10(12pt2):4227s-4232s.
  • 4Riely GJ,Politi KA,Miller VA,et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer.Clin Cancer Res,2006,12 (24):7232-7241.
  • 5Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib.N Engl J Med,2004,350(21):2129-2139.
  • 6Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304(5676):1497-1500.
  • 7Riely GJ,Pao W,Pham D,et al.Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res,2006,12(3ptl):839-844.
  • 8Shigematsu H,Lin L,Takahashi T,et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst,2005,97(5):339-346.
  • 9Kosaka T,Yatabe Y,Endoh H,et al.Mutations of the epidermal growth factor receptor gene in lung cancer:biological and clinical implications.Cancer Res,2004,64 (24):8919 -8923.
  • 10Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.Chest,2005,128 (1):317 -321.

共引文献88

同被引文献37

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部